2. Search Result
Search Result
Results for "

VEGFR-IN-1

" in MedChemExpress (MCE) Product Catalog:

54

Inhibitors & Agonists

1

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101219
    VEGFR-IN-1

    		VEGFR c-Kit EGFR Cancer
    VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively [1].
    VEGFR-IN-1
  • HY-10799
    EG00229 trifluoroacetate
    5+ Cited Publications

    		 Complement System Cancer
    EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to NRP1 b1 domain with an IC50 of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2 .
    EG00229 trifluoroacetate
  • HY-136209
    SU5208

    		VEGFR Cancer
    SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2) .
    SU5208
  • HY-10374
    Semaxinib
    40+ Cited Publications

    SU5416

    		 VEGFR Cancer
    Semaxinib (SU5416) is a potent and selective inhibitor of VEGFR (Flk-1/KDR) with an IC50 of 1.23 μM [1].
    Semaxinib
  • HY-109020
    Acrizanib
    1 Publications Verification

    LHA510

    		 VEGFR Others
    Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-VEGFR-2 .
    Acrizanib
  • HY-12297
    Sulfatinib
    2 Publications Verification

    SurufatINib; HMPL-012

    		 FGFR VEGFR Cancer
    Sulfatinib (Surufatinib) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC50s of in a range of 1 to 24 nM.
    Sulfatinib
  • HY-10981
    Lenvatinib
    50+ Cited Publications

    E7080

    		 VEGFR FGFR PDGFR c-Kit RET Cancer
    Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities [1] .
    Lenvatinib
  • HY-10981A
    Lenvatinib mesylate
    50+ Cited Publications

    E7080 mesylate

    		 VEGFR FGFR PDGFR RET c-Kit Cancer
    Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities [1] .
    Lenvatinib mesylate
  • HY-10337
    Brivanib
    3 Publications Verification

    BMS-540215

    		 VEGFR Autophagy Cancer
    Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β [1].
    Brivanib
  • HY-N7177
    Hydroxytanshinone IIA

    		Drug Metabolite VEGFR Cancer
    Hydroxytanshinone IIA is a hydroxylated metabolite of Tanshinone IIA. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of VEGF/VEGFR2 .
    Hydroxytanshinone IIA
  • HY-10336
    Brivanib (alaninate)
    3 Publications Verification

    BMS-582664

    		 VEGFR Autophagy Cancer
    Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ [1].
    Brivanib (alaninate)
  • HY-18711
    SCR-1481B1 free base

    MetatINib free base; c-Met INhibitor 2 free base

    		 c-Met/HGFR VEGFR Cancer
    SCR-1481B1 free base, also known as Metatinib free base, is a small molecule receptor kinase inhibitor that targets both c-MET and vascular endothelial growth factor receptor 2 (VEGFR2) .
    SCR-1481B1 free base
  • HY-161843
    Necroptosis-IN-4

    		Necroptosis RIP kinase Inflammation/Immunology
    Necroptosis-IN-4, a potent necroptosis inhibitor, is a RIP kinase 1 (RIPK1) inhibitor. Necroptosis-IN-4 has no inhibitory activity against RIPK3 and weak inhibitory activity against VEGFR1/2 and PDGFR-α [1].
    Necroptosis-IN-4
  • HY-10977
    Tivozanib
    5+ Cited Publications

    AV-951; KRN951

    		 VEGFR Cancer
    Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy [1].
    Tivozanib
  • HY-16135A
    CEP-11981 tosylate

    ESK981 tosylate; BOL 303213X tosylate

    		 VEGFR FGFR Others Cancer
    CEP-11981 (tosylate) (ESK981 (tosylate), BOL 303213X (tosylate)) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, VEGFR1-3 and FGFR1, and has potential anti-tumor and anti-angiogenic effects [1].
    CEP-11981 tosylate
  • HY-13308
    Regorafenib Hydrochloride
    Maximum Cited Publications
    59 Publications Verification

    BAY 73-4506 hydrochloride

    		 VEGFR Autophagy PDGFR Raf RET Cancer
    Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively [1].
    Regorafenib Hydrochloride
  • HY-10977A
    Tivozanib hydrochloride hydrate
    5+ Cited Publications

    AV-951 hydrochloride hydrate; KRN951 hydrochloride hydrate

    		 VEGFR Cancer
    Tivozanib hydrochloride hydrate is the hydrate hydrochloride form of Tivozanib (HY-10977). Tivozanib hydrochloride hydrate is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrochloride hydrate exhibits antitumor efficacy [1].
    Tivozanib hydrochloride hydrate
  • HY-149512
    FGFR1/VEGFR2-IN-1

    		FGFR VEGFR Cancer
    FGFR1/VEGFR2-IN-1 (compound 2b) is an FGFR1/VEGFR2 inhibitor. FGFR1/VEGFR2-IN-1 can be used for cancer research [1].
    FGFR1/VEGFR2-IN-1
  • HY-133980
    O-Demethyl Lenvatinib

    		Drug Metabolite Cancer
    O-Demethyl Lenvatinib is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities [1] .
    O-Demethyl Lenvatinib
  • HY-16135
    CEP-11981

    ESK981; BOL 303213X

    		 VEGFR FGFR Cancer
    CEP-11981(ESK981; BOL 303213X) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, VEGFR1-3 and FGFR1, and has potential anti-tumor and anti-angiogenic effects [1].
    CEP-11981
  • HY-12297R
    Sulfatinib (Standard)

    		FGFR VEGFR Cancer
    Sulfatinib (Standard) is the analytical standard of Sulfatinib. This product is intended for research and analytical applications. Sulfatinib (Surufatinib) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC50s of in a range of 1 to 24 nM.
    Sulfatinib (Standard)
  • HY-19624
    NVP-ACC789

    ACC-789; ZK202650

    		 VEGFR PDGFR Cancer
    NVP-ACC789 is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC50s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.
    NVP-ACC789
  • HY-133980A
    O-Demethyl Lenvatinib hydrochloride

    		Drug Metabolite Cancer
    O-Demethyl Lenvatinib hydrochloride is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET. Lenvatinib shows potent antitumor activities [1] .
    O-Demethyl Lenvatinib hydrochloride
  • HY-10981AR
    Lenvatinib mesylate (Standard)

    		VEGFR FGFR PDGFR RET c-Kit Cancer
    Lenvatinib (mesylate) (Standard) is the analytical standard of Lenvatinib (mesylate). This product is intended for research and analytical applications. Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities [1] .
    Lenvatinib mesylate (Standard)
  • HY-10981R
    Lenvatinib (Standard)

    		VEGFR FGFR PDGFR c-Kit RET Cancer
    Lenvatinib (Standard) is the analytical standard of Lenvatinib. This product is intended for research and analytical applications. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities [1] .
    Lenvatinib (Standard)
  • HY-I0678
    Regorafénib N-oxyde (M2)

    		Drug Metabolite PDGFR Cancer
    Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
    Regorafénib N-oxyde (M2)
  • HY-112467
    Tivozanib hydrate
    5+ Cited Publications

    AV-951 hydrate; KRN951 hydrate

    		 VEGFR Cancer
    Tivozanib hydrate (AV-951 hydrate; KRN951 hydrate) is the hydrate form of Tivozanib (HY-10977). Tivozanib hydrate is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrate exhibits antitumor efficacy [1].
    Tivozanib hydrate
  • HY-10337R
    Brivanib (Standard)

    		VEGFR Autophagy Cancer
    Brivanib (Standard) is the analytical standard of Brivanib. This product is intended for research and analytical applications. Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β [1].
    Brivanib (Standard)
  • HY-10229
    Motesanib Diphosphate
    5 Publications Verification

    AMG 706 Diphosphate

    		 c-Kit VEGFR Cancer
    Motesanib Diphosphate (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret.
    Motesanib Diphosphate
  • HY-10207
    Dovitinib lactate
    5+ Cited Publications

    CHIR-258 lactate; TKI-258 lactate

    		 FLT3 c-Kit FGFR VEGFR PDGFR Cancer
    Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively [1].
    Dovitinib lactate
  • HY-B0062
    Dovitinib lactate hydrate

    TKI258 lactate hydrate; CHIR-258 lactate hydrate

    		 FLT3 c-Kit FGFR VEGFR PDGFR Cancer
    Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively [1].
    Dovitinib lactate hydrate
  • HY-50904
    Nintedanib
    45+ Cited Publications

    BIBF 1120

    		 PDGFR VEGFR FGFR Cancer
    Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
    Nintedanib
  • HY-120640
    BMS-605541

    		VEGFR PDGFR Cancer
    BMS-605541 is a selective and orally active inhibitor of VEGFR-2 kinase with an IC50 value of 23 nM and Ki value of 49 nM. BMS-605541 inhibits the activity of Flk-1, VEGFR-1 and PDGFR-β with IC50 values of 40 nM, 400 nM and 200 nM, respectively. BMS-605541 can be used for cancer research [1].
    BMS-605541
  • HY-11106
    Nintedanib esylate
    45+ Cited Publications

    BIBF 1120 esylate

    		 PDGFR VEGFR FGFR Cancer
    Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
    Nintedanib esylate
  • HY-168597
    FGFR1/VEGFR2-IN-3

    		FGFR Apoptosis VEGFR Cancer
    FGFR1/VEGFR2-IN-3 (Compound 8m) is a dual inhibitor of FGFR1/VEGFR2. FGFR1/VEGFR2-IN-3 exhibits anti-proliferative and anti-migratory activities against cancer cells, and is capable of inducing cell apoptosis [1].
    FGFR1/VEGFR2-IN-3
  • HY-10331
    Regorafenib
    Maximum Cited Publications
    59 Publications Verification

    BAY 73-4506

    		 VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie Cancer
    Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity [1].
    Regorafenib
  • HY-10331A
    Regorafenib monohydrate
    Maximum Cited Publications
    59 Publications Verification

    BAY 73-4506 monohydrate

    		 VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie Cancer
    Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity [1].
    Regorafenib monohydrate
  • HY-10331B
    Regorafenib mesylate

    BAY 73-4506 mesylate

    		 VEGFR PDGFR RET Raf c-Kit FGFR Autophagy Tie Cancer
    Regorafenib (BAY 73-4506) mesylate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib mesylate shows very robust antitumor and antiangiogenic activity [1].
    Regorafenib mesylate
  • HY-164387
    Sutetinib

    		EGFR PDGFR VEGFR Cancer
    Sutetinib is an orally active inhibitor for tyrosine kinase, that is associated with tumor growth and angiogenesis, such as VEGFR (Ki= 0.009 µM for VEGFR-1/2/3), PDGFR (Ki= 0.008 µM for PDGFR-α/β) and proto-oncogene cKIT. Sutetinib inhibits the proliferation, migration, and tubular structure formation of endothelial cells and fibroblasts, and exhibits board-spectrum antitumor efficacy in vitro and in vivo [1].
    Sutetinib
  • HY-50904R
    Nintedanib (Standard)

    		PDGFR VEGFR FGFR Cancer
    Nintedanib (Standard) is the analytical standard of Nintedanib. This product is intended for research and analytical applications. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
    Nintedanib (Standard)
  • HY-164387A
    Sutetinib maleate

    		EGFR VEGFR PDGFR Cancer
    Sutetinib maleate is the maleate form of Sutetinib (HY-164387). Sutetinib maleate is an orally active inhibitor for tyrosine kinase, that is associated with tumor growth and angiogenesis, such as VEGFR (Ki= 0.009 µM for VEGFR-1/2/3), PDGFR (Ki= 0.008 µM for PDGFR-α/β) and proto-oncogene cKIT. Sutetinib maleate inhibits the proliferation, migration, and tubular structure formation of endothelial cells and fibroblasts, and exhibits board-spectrum antitumor efficacy in vitro and in vivo [1].
    Sutetinib maleate
  • HY-135366
    HPN-01

    		IKK Inflammation/Immunology
    HPN-01 is a potent and selective IKK inhibitor, with pIC50 values of 6.4, 7.0 and <4.8 for IKK-α, IKK-β and IKK-ε, respectively. HPN-01 displays greater 50-fold selectivity over a panel of more than 50 other kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2 .
    HPN-01
  • HY-149415
    Multi-kinase-IN-5

    		RET FGFR VEGFR c-Kit c-Met/HGFR PDGFR Raf Cancer
    Multi-kinase-IN-5 (compound 15c) is a promising multi-kinase inhibitory agent. Multi-kinase-IN-5 inhibits a panel of protein kinases (RET, KIT, cMet, VEGFR1,2, FGFR1, PDGFR and BRAF), showing % inhibition of 74%, 31%, 62%, 40%, 73%, 74%, 59%, and 69%, respectively, and IC50 of 1.287, 0.117 and 1.185 μM against FGFR1, VEGFR, and RET kinases, respectively [1].
    Multi-kinase-IN-5
  • HY-10331R
    Regorafenib (Standard)

    		VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie Cancer
    Regorafenib (Standard) is the analytical standard of Regorafenib. This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity [1].
    Regorafenib (Standard)
  • HY-11106R
    Nintedanib esylate (Standard)

    		PDGFR VEGFR FGFR Cancer
    Nintedanib esylate (Standard) is the analytical standard of Nintedanib esylate. This product is intended for research and analytical applications. Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
    Nintedanib esylate (Standard)
  • HY-10331AR
    Regorafenib monohydrate (Standard)

    		VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie Cancer
    Regorafenib (monohydrate) (Standard) is the analytical standard of Regorafenib (monohydrate). This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity [1].
    Regorafenib monohydrate (Standard)
  • HY-P990088
    Sotiburafusp alfa

    		VEGFR PD-1/PD-L1 Cardiovascular Disease
    Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker 101GGSGGSGGSGGSGGS 115 to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor [1].
    Sotiburafusp alfa
  • HY-50905
    Dovitinib
    5+ Cited Publications

    CHIR-258; TKI258

    		 FLT3 c-Kit FGFR VEGFR PDGFR c-Fms Cancer
    Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity [1] .
    Dovitinib
  • HY-10230
    Midostaurin
    25+ Cited Publications

    PKC412; CGP 41251

    		 PKC VEGFR c-Kit NO Synthase Apoptosis Cancer
    Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM [1] . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .
    Midostaurin
  • HY-150026
    Multi-kinase-IN-2

    		VEGFR PDGFR FGFR c-Kit Akt Src Apoptosis Cancer
    Multi-kinase-IN-2 (compound 7h) is an orally active and potent angiokinase inhibitor. Multi-kinase-IN-2 exhibits excellent inhibitory activity against angiokinases including VEGFR-1/2/3, PDGFRα/β, and FGFR-1, as well as LYN and c-KIT kinases. Multi-kinase-IN-2 significantly attenuates phosphorylation of AKT and ERK proteins. Multi-kinase-IN-2 induces cell apoptosis. Multi-kinase-IN-2 shows anticancer activity [1].
    Multi-kinase-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: